<DOC>
	<DOCNO>NCT01214915</DOCNO>
	<brief_summary>The purpose study investigate effective safe SPD422 ( Anagrelide Hydrochloride ) Japanese subject , diagnose Essential Thrombocythemia , 's previously treatment either effective cause unacceptable adverse reaction . The study aim show platelet count safely reduce treated patient 600 x 10^9/L minimum three month treatment . To demonstrate positive effect platelet level need remain 600 x 10^9/L least 4 week .</brief_summary>
	<brief_title>Effect SPD422 Platelet Lowering Safety Japanese Adults With At Risk Essential Thrombocythaemia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Anagrelide</mesh_term>
	<criteria>Subjects must previously treat cytoreductive therapy intolerant refractory therapy . Subjects underlying condition medication would confound study analysis interact study medication .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>